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Clinical Practice Guideline for Accurate Diagnosis and Effective 
Treatment of Gastrointestinal Stromal Tumor in Korea
Despite the rarity in incidence and prevalence, gastrointestinal stromal tumor (GIST) has 
emerged as a distinct pathogenetic entity. And the clinical management of GIST has been 
evolving very rapidly due to the recent recognition of its oncogenic signal transduction 
pathway and the introduction of new molecular-targeted therapy. Successful management 
of GIST requires a multidisciplinary approach firmly based on accurate histopathologic 
diagnosis. However, there was no standardized guideline for the management of Korean 
GIST patients. In 2007, the Korean GIST study group (KGSG) published the first guideline for 
optimal diagnosis and treatment of GIST in Korea. As the second version of the guideline, 
we herein have updated recent clinical recommendations and reflected changes in 
diagnosis, surgical and medical treatments for more optimal clinical practice for GIST in 
Korea. We hope the guideline can be of help in enhancing the quality of diagnosis by 
members of the Korean associate of physicians involving in GIST patients’ care and 
subsequently in achieving optimal efficacy of treatment.
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INTRODUCTION
Gastrointestinal stromal tumor (GIST) is relatively rare neo-
plasm occurring in the gastrointestinal tract, omentum, or mes-
entery, but is the most common among sarcoma of the gastro-
intestinal tract and accounts for 5% of all sarcoma. In general, 
only complete resection can lead to cure, but recurrence in the 
liver and peritoneum is common after surgery, and unresect-
able or recurrent tumor does not respond to conventional cyto-
toxic chemotherapy and therefore, its prognosis has been very 
poor. However, the identification of signal transduction path-
way associated with the development of GISTs and the use of 
so-called molecular targeted therapy with imatinib (Glivec, No-
vartis Korea, Seoul, Korea) have yielded remarkable achieve-
ment. In addition, imatinib has been shown not only the pro-
longation of survival time but also the great effectiveness on 
quality of life with very mild side effects compared with con-
ventional cytotoxic chemotherapy. Based on these results, ima-
tinib is used as first-line therapy in metastatic GISTs, and fur-
thermore, neoadjuvant and adjuvant treatments with imatinib 
are being investigated. 
  In the western countries, histopathologic criteria and molec-
ular pathologic mechanism of GIST have recently standardized 
and the guidelines for this entity have been published by the 
National Comprehensive Cancer Network (NCCN) (1) and the 
European Society of Medical Oncology (ESMO) (2). And in Ja-
pan and Australia, the guidelines appropriate for clinical prac-
tice in each country have been also published (3, 4)
  However, in Korea, no standardized guidelines for diagnosis 
or treatment of GISTs are available. As a result, diagnosis is not 
consistent between institutions and in addition to the problem 
associated with diagnosis, optimal treatments are sometimes 
not provided because of numerous uncertainties related to treat-
ment and a lack of treatment guidelines. To recognize and to 
find ways to solve these problems, pathologists, surgeons, gas-
troenterologists, diagnostic radiologists, and medical oncolo-
gists organized a multidisciplinary study group called the Kore-
an GIST Study Group (KGSG) in December in 2006. We made 
the first guideline in 2007 for diagnosis and treatment of GISTs 
that is suitable for clinical practice in Korea (5). In this second 
version of the guideline, we sought to update changes in the 
topics and reflect modified and added recommendations. Ex-Kang Y-K, et al.  •  Diagnosis and Management of GIST in Korea
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pert panel members of the KGSG thoroughly reviewed the rele-
vant literature including the European Society of Medical On-
cology and National Comprehensive Cancer Network guide-
lines and shared their experience and opinions to make a con-
sensus on twenty topics related to pathologic diagnosis, surgical 
and medical treatment of GIST. The consensus was presented as 
the basis for a guideline of diagnosis and treatment for patients 
with GIST that would be used to facilitate the optimal clinical 
practice in Korea.
PATHOLOGIC DIAGNOSIS OF GIST
Definition of GIST
GIST is the most common mesenchymal tumor of the gastroin-
testinal tract (6). GISTs arise from the interstitial cells of Cajal or 
their common stem cell (7). GISTs range in size from tiny tu-
mors discovered incidentally during tests for other diseases, 
measuring less than 1 cm to very large lesions measuring up-
wards of 35 cm (median 5 cm) (8). Irrespective of tumor size, 
GISTs share morphologic features and immunoreactivity for 
KIT and contain an oncogenic mutation in the KIT (80–85%) or 
platelet-derived growth factor receptor (PDGFRA, 5–7%) genes 
(9). GISTs can arise in any portion of the gastrointestinal tract, 
but usually occur in the stomach (60%) or the small intestine 
(30%) (10, 11). 
 
Pathologic findings of GIST
On gross examination, GIST is a well circumscribed, fleshy, pink, 
or tan-white mass. Large tumors frequently show hemorrhage, 
necrosis, and cystic degeneration. Microscopically, GISTs can 
be divided into three different histologic subgroups. Spindle 
cell GISTs (70%) are composed of cells with palely eosinophilic, 
fibrillary cytoplasm, ovoid uniform nuclei, and ill-defined cell 
borders, often with a somewhat syncytial appearance, arranged 
in short fascicles or whorls (Fig. 1). Epithelioid GISTs (20%) are 
composed of rounded cells with eosinophilic to clear cytoplasm 
arranged in sheets and nests (Fig. 2). The final group shows mixed 
spindle and epithelioid cells (10%). The frequency of these his-
tological types varies according to location. GISTs of the stom-
ach mostly fall into one of 4 spindle cell subtypes of sclerosing, 
palisading-vacuolated, hypercellular, and sarcomatous or one 
of 4 epitheloid subtypes of sclerosing epitheloid variant, dysco-
hesive epithelioid, hypercellular, and sarcomatous (12). GISTs 
of the small intestine have great amounts of skeinoid fiber, and 
are most likely to become malignant if epitheloid type or mixed 
type is present. Many of GISTs in the large intestine are spindle 
cell type. GISTs developed in the omentum are similar to histo-
logical types of the stomach whereas GISTs of the mesentery 
are similar to histological findings of the small intestine. The di-
agnosis of GISTs is mainly based on clinical and histological 
findings, but immunohistochemical staining is needed to con-
firm diagnosis (13). 
Immunohistochemical staining of GIST
The most important immunohistochemical staining in the di-
agnosis of GISTs is c-kit (CD 117), and other several antibodies 
may be helpful in the diagnosis and differential diagnosis. Ap-
proximately ~95% of cases are positive for c-kit protein (Figs. 1, 2). 
A B
Fig. 1. Typical photomicrograph of spindle cell gastrointestinal stromal tumor (A: H&E, ×400) and c-kit stained in the cytoplasm and cytoplasmic membranes (B: Immunohisto-
chemical stain, ×400). Blood vessels within the tumor are negative for c-kit (B).Kang Y-K, et al.  •  Diagnosis and Management of GIST in Korea
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c-kit negative GISTs account for ~5% of cases and can cause di-
agnostic difficulties, but given the rather limited choice in mes-
enchymal diagnostic considerations at these sites, they can often 
be diagnosed by excluding other potential mimics by immuno-
histochemical characterization (14). c-kit staining with polyclonal 
anti-c-kit antibody is mandatory for diagnosis. Extreme caution 
should always be taken to avoid false-positive or false-negative 
c-kit staining results by carefully observing positive control (mast 
cells or interstitial cells of Cajal) and negative control (smooth 
muscle cells or endothelial cells). Because c-kit may also be pos-
itive for other soft tissue tumors, interpretation of c-kit based on 
H&E findings is necessary (Table 1). 
  CD34 is positive in 60-80% of GISTs, and the frequency of 
CD34 positivity depends on location of GISTs. The frequency of 
positive CD34 is high in GISTs of the esophagus and colon (95%), 
but relatively low in the small bowel and extra-gastrointestinal 
sites. In the small intestine, CD34 is positive in 50% of cases while 
c-kit is positive in almost 100% of cases. However, GISTs of the 
colon can readily be misdiagnosed as other soft tissue tumors 
such as inflammatory fibroid polyp or inflammatory myofibro-
blastic tumor, which is attributable to the rare occurrence of 
GISTs in the colon and greater incidence of negative or focal 
staining of c-kit in GISTs of the colon relative to other organs. 
Thus, negativity of c-kit staining does not exclude a possibility of 
GIST, and every effort should be made to obtain the diagnosis 
of GISTs through proper differential diagnoses. Protein kinase C 
(PKC)-theta staining is positive in approximately 90% of GISTs. 
The quality of PKC-theta staining must be managed by observ-
ing ganglion cells of the intermyenteric plexus as an internal pos-
itive control and smooth muscle or blood vessel as a negative 
control. When the staining is properly performed, it can serve 
as an important adjunct tool in the diagnosis of c-kit negative 
GISTs, particularly developed in the stomach and extragastro-
intestinal locations (15). H-caldesmon is positive in 60-80% of 
GISTs, which may be helpful in the diagnosis of c-kit negative 
GISTs. Smooth muscle actin is positive in 30-40% of GISTs, and 
the frequency of the positive staining is high especially in the 
small bowel. S-100 and desmin is positive in 5% and 1-2% of 
GISTs, respectively. A recently developed antibody against DOG1 
(discovered on GIST) was reported to be superior in sensitivity 
and specificity to c-kit and CD34. However, c-kit negative GISTs 
express DOG1 in only 36% of cases, limiting its use in this set-
ting (16). Fig. 3 shows the algorithm of diagnosis in GISTs based 
on the immunohistochemical staining results.
 
A B
Fig. 2. Typical photomicrograph of epithelioid gastrointestinal stromal tumor (A: H&E, ×400) and c-kit stained in the cytoplasm and cytoplasmic membranes (B: Immunohisto-
chemical stain, ×400).
Table 1. Recommended immunohistochemical markers for gastrointestinal stromal 
tumors (GIST) and some other immunoreactive tumors (12, 13, 15, 17-19)
Antibody % positive in GIST Some other immuno-reactive tumors
c-kit (CD117)   90-95 Melanoma, PEComa, clear cell 
sarcoma
CD34 80-85% of gastric GIST
50% of small intestinal GIST
SFT, spindle cell lipoma, 
PNST, vascular lesion
PKC-theta 90 PNST, smooth muscle tumor, desmoid
h-caldesmon 60-80   Smooth muscle tumor
SMA 30-40 Smooth muscle/myofibroblastic tumor
S-100 5 Melanoma, PNST, granular cell tumor
Desmin 1–2 Smooth muscle tumor
PEComa, perivascular epithelioid cell tumor; PNST, peripheral nerve sheath tumors; 
SFT, solitary fibrous tumor; SMA, smooth muscle actin; PKC, protein kinase C.Kang Y-K, et al.  •  Diagnosis and Management of GIST in Korea
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Extragastrointestinal GISTs (EGISTs)
In addition to the gastrointestinal tract, GISTs are also found in 
extragastrointestinal sites, although rare. Caution should be tak-
en because histological and immunohistochemical findings of 
EGISTs are different from those of GISTs and consequently, it 
may be very difficult to make a diagnosis.
c-kit negative GISTs
In GISTs, c-kit is negative in ~5% of cases. These c-kit negative 
GISTs are common in the stomach and omentum/mesentery. 
In such cases, examining other immunohistochemical markers 
(PKC-theta, CD34, SMA or DOG1) and mutation analyses may 
be useful in diagnosis. Among c-kit negative GISTs, 75% are posi-
tive for PKC-theta, 44% for CD34, 40% for SMA, and 36% for DOG1 
(14, 15, 17-19). 
Pathologic prognostic parameters
Morphologic risk assessment in GISTs provides the basis for 
clinical management and optimal patient care. The vast major-
ity of studies of GISTs suggest that the two most important prog-
nostic features to assess the risk of aggressive behavior in a pri-
mary localized GIST are mitotic activity and tumor size. These 
two features were the foundation of the consensus approach for 
risk assessment in GISTs published by Fletcher and colleagues 
in 2002 (13). Subsequent data collected by Miettinen and col-
leagues (20), analyzing large series of GISTs, confirmed that tu-
mor size and mitotic activity are essential prognostic parame-
ters; they proposed additional new parameter, location of tu-
mor, in the evaluation of the clinical behavior of localized GISTs, 
and KGSG adopted this risk stratification with slight modifica-
tion (Table 2) (12). 
Pathologic reporting for GIST
It has been suggested that one block per centimeter should be 
examined histologically. The pathology report should include 
the size of the tumor, mitosis (per 50 high powered fields [HPF]), 
location, resection margin status, and the presence or absence 
of metastases. Presence of metastasis or perforation during op-
eration leads to a diagnosis of malignant GIST. Pathologic report 
may include histological type including the degree of cellularity 
and atypia, presence of necrosis or cystic change, invasion into 
mucosa or adjacent structures.
Mutational analysis 
At present, mutation analysis is not required for the diagnosis 
of GIST when tumors have a typical histology and immunohis-
tochemical staining pattern. However, because the presence 
and location of mutations in KIT or PDGFRA can have implica-
tions for prognosis and management in patients with advanced 
disease, mutation analysis should be considered at the time of 
diagnosis. Mutational analysis for KIT exons 9, 11, 13, and 17 or 
PDGFRA exons 12, 14, and 18 can be performed with unstained 
slides from formalin-fixed paraffin-embedded tissue or fresh 
frozen tissue.
SURGICAL TREATMENT OF GIST
Surgical treatment as first-line therapy
The main treatment of resectable localized GIST is surgery. The 
goal is complete resection without residual tumor cells (R0).
Diagnosis
The initial diagnosis is generally made by endoscopy, endoscop-
ic ultrasound, gastrography, or computed tomography (CT) of 
the abdomen due to difficulty with obtaining adequate tissues. 
It should be confirmed by pathologic histological findings after 
resection. Preoperative histological diagnosis is feasible, but it 
may be difficult to interpret definitively (21-24). Imaging tests 
to detect metastasis include chest radiography (or chest CT), 
triphasic CT of the abdomen and pelvis, and/or magnetic reso-
nance imaging (MRI) if necessary (25). Positron emission to-
Table 2. Newly proposed risk stratification of primary localized gastrointestinal stromal 
tumors (12)
Group
Tumor parameters
Patients with progressive disease 
during follow-up and 
characterization of malignant 
potential (%)
Size, cm
Mitotic rate per 
50 HPFs
Gastric GISTs
Non-gastric 
GISTs
1 ≤2 ≤5 Very low (0) Very low (0)
2 >2 ≤5 ≤5 Low (1.9) Low (4.3)
3a >5 ≤10 ≤5 Low (3.6) Intermediate (24)
3b >10 ≤5 Intermediate (12) High (52)
4 ≤2 >5 Low*(0) High*(50)
5 >2 ≤5 >5 Intermediate (16) High (73)
6a >5 ≤10 >5 High (55) High (85)
6b >10 >5 High (86) High (90)
*Denotes tumor categories with very small numbers of cases insufficient for prediction 
of malignant potential.
HPF, high power field.
Fig. 3. Algorithm to diagnose gastrointestinal stromal tumor based on immunohisto-
chemistry.
KIT(+) (~95%)
Desmin (-)
S-100 (-)
S-100 (+)
KIT(-) (~5%)
CD34(+) CD34(+) CD34(-) CD34(-)
GIST
Desmin (+)
Smooth muscle tumor Schwannoma
~70% ~30%Kang Y-K, et al.  •  Diagnosis and Management of GIST in Korea
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mography (PET) may be performed when evidence of metasta-
sis may be equivocal or for clinical trials (21).
Biopsy
There is no consensus regarding the need of endoscopic ultra-
sound biopsy or percutaneous biopsy for preoperative diagno-
sis. The important part of histological diagnosis is not to cause 
tumor seeding during biopsy. Therefore, unless multiple metas-
tases are present, excisional biopsy with laparotomy is suggest-
ed (21, 26). If diagnosis is unknown at the time of resection, post-
operative frozen tissue examination must be performed in order 
to elucidate the treatment strategy for GIST as treatment varies 
for an adenocarcinoma or lymphoma. Biopsy is necessary when 
planning neoadjuvant therapy.
Indications for surgery
Due to the high potential for malignancy of GIST, resection 
should be the first-line treatment (21, 27). We strongly recom-
mend resection for tumors larger than 2 cm or growing tumors 
(21). Smaller tumors (<2 cm) confer a lower potential for malig-
nancy and may be observed. However, small tumor size does 
not exclude the potential for malignant transformation. There-
fore, patients should be informed about the possibility of malig-
nancy. 
Surgical margins
The main objectives of surgical treatment are to acquire nega-
tive margins and to resect without causing tumor rupture. In 
case of inadvertent tumor infiltration into the surrounding or-
gans, a complete en bloc resection with negative margins should 
be performed (21, 26, 27) regardless of size. Therefore, even tu-
mors are small, endoscopic shell-out procedure or enucleation 
should be avoided if GIST is suspected. In many cases, wedge 
resection of gastric GIST and segmental resection of small bow-
el GIST are appropriate treatments. Subtotal or total gastrecto-
my may be performed based on size and location. We recom-
mend en bloc resection for omental or mesenteric GIST. Adja-
cent organs adherent to tumor should also be completely re-
sected en bloc to avoid tumor rupture or intraabdominal seed-
ing (26).
Laparoscopic resection 
Laparoscopic resection is feasible if intraabdominal tumor rup-
ture or seeding is unlikely. Laparoscopic resection should fol-
low principles of oncologic surgery. Generally, it is reserved for 
small, favorably located gastric GISTs (28-31). Intra-operative 
endoscopy or laparoscopic ultrasound may be used to assist in 
laparoscopic resection if needed.
Lymphadenectomy 
Unlike adenocarcinoma, GIST rarely metastasizes to local re-
gional lymph nodes. Therefore, lymphadenectomy is warranted 
only if metastasis is suspected, i.e. enlarged lymph nodes.
Post-operative follow-up and Surveillance
For patients in the high- or intermediate-risk group, we recom-
mend follow-up with CT of the abdomen and pelvis every 3 to  
4 months for the first 3 yr after surgery and then every 6 months 
until 5 yr; then annually thereafter (21, 26). For patients in the 
low or very low risk, we recommend follow-up with CT every 6 
months for 5 yr. Ultrasonography may replace CT once a year 
(21, 26).
  The role of PET for this purpose is not established, and clini-
cal studies on the role of PET are ongoing. Most recurrences oc-
cur within 2 yr after surgery and the liver and peritoneum are 
the most common sites of recurrence (32). Due to the high inci-
dence of gastric cancer in Korea, the National Cancer Screening 
program recommends biennial stomach-cancer screening for 
men and women older than 40 yr with endoscopy or upper-gas-
trointestinal series.
Post-imatinib resection in metastatic GIST 
Medical treatment with imatinib alone usually does not result 
in complete response in metastatic GIST. And, responses are 
not usually maintained indefinitely. It is now well recognized 
that clones of tumor cells resistant to imatinib develop continu-
ously over time after start of imatinib. Therefore, in cases where 
partial or stable responses are shown after adequate duration 
of imatinib therapy (usually 4 to 12 months of treatment), com-
plete surgical resection of residual tumor may be considered to 
reduce the risk of development of resistant clones by eradicat-
ing the residual viable tumor cells. Several retrospective studies 
suggested that resection of residual lesions could prolong pro-
gression-free survival if it is done during the tumors are under 
control with imatinib (either in PR or SD) (33, 34). It is also em-
phasized that imatinib should be continued after resection (21). 
However, the role of resection of residual tumors after imatinib 
therapy has not been established, and several phase III clinical 
trials to investigate the role of surgical resection in this setting 
are ongoing or planned worldwide. Hepatic or peritoneal me-
tastases may be locally treated with radiofrequency ablation 
(RFA) or chemoembolization. Importantly, management of 
GIST should be coordinated by a multidisciplinary team of ex-
perienced medical and surgical specialists.
MEDICAL TREATMENT OF GIST
 
Adjuvant treatment
Adjuvant treatment with imatinib is given to enhance the pos-
sibility of cure by eradicating microscopic lesions that might still 
be present after complete resection of visual tumors. Given the 
great efficacy of imatinib on metastatic or recurrent GIST, ima-Kang Y-K, et al.  •  Diagnosis and Management of GIST in Korea
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tinib appears to have a sufficient potential as adjuvant treatment. 
  In recently published ACOSOG Z9001 study of patients with 
tumor diameter ≥3 cm who received imatinib for 1 yr following 
complete resection, imatinib demonstrated a significant increase 
in recurrence-free survival (RFS) compared with placebo although 
improvement in overall survival (OS) not observed (35). The 
benefit in RFS appears to be related to tumor size, with the most 
marked improvement in patients who had large tumor (≥10 cm) 
in the study.
  A Korean phase II study, recently presented in an abstract, 
evaluated the efficacy of 2-yr imatinib adjuvant therapy in pa-
tients who were at high risk of recurrence (tumor size ≥5 cm and 
mitotic index ≥5/50 HPF, tumor size ≥10 cm, or mitotic index 
≥10/50 HPF) based on the NIH risk criteria and had KIT exon 
11 mutation which had been recognized as an independent 
poor risk factor of recurrence in a Korean retrospective study 
(36, 37). The recurrence-free survival of these patients looked 
much improved compared with historic data. 
  These results strongly suggest that adjuvant imatinib therapy 
should be recommended to reduce the risk of recurrence after 
curative resection of localized GISTs. However, there are several 
issues to solve with regard to adjuvant treatment with imatinib. 
In the ACOSOG Z9001 trial, rapid disease recurrence was ob-
served after stopping 1 yr of imatinib adjuvant treatment. The 
study did not demonstrate a benefit of adjuvant imatinib in terms 
of overall survival. Adjuvant treatment with imatinib may delay 
recurrence. But, it may not increase the cure rate or eliminate 
the disease in patients with metastatic GISTs; therefore the ma-
jority of them eventually develop resistance to imatinib, leading 
to treatment failure despite its great efficacy. Although currently 
it remains yet to be determined whether adjuvant imatinib im-
proves cure rate or just delays recurrence, adjuvant imatinib can 
be proposed as an option for patients at a substantial risk of re-
lapse. Only tumor size and mitotic count were included in the 
2002 NIH Consensus risk classification. More recent risk classi-
fications incorporate primary tumor site and/or tumor rupture 
in addition to the tumor size and mitotic count. Current consen-
sus of the experts is to recommend adjuvant imatinib for patients 
at high risk of relapse and not for those at low risk of relapse. But, 
there is no consensus for the patients at intermediate risk (20, 
38). Patients with tumor rupture should be considered as hav-
ing high likelihood of micrometastasis and treated with imatinib. 
In addition to the risk assessment, mutational analysis may be 
helpful for the selection of patients who are not likely to get ben-
efit from the treatment. For example, GIST with D842V muta-
tion in PDGFRα exon 18 is known to be not responsive to ima-
tinib. With the currently available data, it is recommended to 
use imatinib as an adjuvant treatment for at least one year. And, 
most of the experts agree that 1 yr of adjuvant imatinib is not 
long enough for especially patients at high risk. However, opti-
mal duration of adjuvant imatinib remains yet to be determined. 
Phase III trials comparing one year versus three years and no 
treatment versus two years of treatment duration are ongoing. 
 
Neoadjuvant treatment
Outside of a clinical trial, neoadjuvant treatment with imatinib 
is not recommended unless there are clinically significant 
grounds to improve results of surgery by downsizing tumors 
with neoadjuvant therapy at the initial diagnosis (21). However, 
neoadjuvant treatment with imatinib may be considered if R0 
resection is not feasible, for the purpose of preserving organ 
functions in GISTs of the rectum, esophagus, and duodenum, 
or for complete resection of gastric GISTs accompanied by se-
vere, local infiltration into the pancreas or duodenum (39-41). 
When such a neoadjuvant treatment is considered, progression 
and response of tumors before and during the treatment should 
be assessed very carefully by CT and/or PET scan, and it should 
be done by an experienced multidisciplinary team. Early assess-
ment of tumor response by CT and/or PET is recommended so 
that surgery is not delayed in the case of non-responding tumors. 
Duration of neoadjuvant therapy with imatinib may vary accord-
ing to response to the treatment, but surgery should be performed 
after sufficient shrinkage of tumors is observed (typically after 4 
to 6 months and within 12 months of imatinib treatment) (21). 
Mutational analysis might be helpful to exclude GISTs not sen-
sitive to imatinib.
Advanced disease
Initiation of imatinib
Once an advanced GIST is diagnosed, imatinib should be im-
mediately initiated regardless of the presence or absence of 
symptoms. It is optimal to administer imatinib in patients with 
liver metastasis or localized metastasis to the peritoneum be-
cause cure is hard to achieve even if tumors are completely re-
sected visually and histologically (32, 42). The concept of adju-
vant therapy does not apply in this setting. 
Optimal dosage of imatinib
The optimal initial dose of imatinib is 400 mg per day. In a large 
European phase III study that compared 400 mg daily with 800 
mg daily, the group with 800 mg daily did not achieve an in-
creased survival rate while side effects were increased (43, 44). 
However, in subgroup analysis, a clinically significant improve-
ment of progression-free survival was observed in the group 
with KIT exon 9 mutations that received 800 mg per day. So, 
high dose imatinib is now recommended in the Western coun-
tries as the initial treatment for patients with KIT exon 9 mutant 
GIST (45). However, it is still unclear if this recommendation is 
valid for Asian patients as well. In recent two retrospective stud-
ies of Korean and Taiwanese patients with GIST, there was no 
difference in the treatment outcomes according to the KIT gen-
otype with imatinib administered at a dose of 400 mg per day Kang Y-K, et al.  •  Diagnosis and Management of GIST in Korea
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(37), which suggest that 400 mg/day of imatinib might be enough 
for KIT exon 9 mutant GIST patients in Asia. A larger scale ret-
rospective study is ongoing to address this issue.
Duration of imatinib treatment and surgical resection of responding 
tumors
Treatment with imatinib should be continued indefinitely un-
less disease progresses, intolerable adverse events occur, or a 
patient refuses the treatment. If imatinib is discontinued after 
tumor response with imatinib is achieved, the disease progresses 
in most cases. Many patients show responses to the reintroduc-
tion of imatinib when the disease progresses following imatinib 
discontinuation, but imatinib treatment should not be interrupt-
ed outside of a clinical trial or unless clinically indicated. Surgi-
cal resection of stabilized tumor lesions can be considered op-
tionally with enough discussion and with a multidisciplinary 
approach.
Standard tests for tumor response
CT is the most useful tool to date to determine response to 
treatments. We recommend dynamic or triphasic CT scanning 
through arteries and veins after contrast enhancement (25). 
Fluourodeoxyglucose (FDG) PET is highly sensitive in early tu-
mor response, but given its cost and availability, it is not easy to 
include it in basic imaging tests (46-48). Intervals to determine 
response may be various according to clinical situations, and 
tumor response is usually determined every 3 to 4 months after 
the initial response is confirmed.
Criteria for determination of response
Determining tumor response or continuation of treatment sole-
ly based on tumor size should be avoided because tumors may 
enlarge due to intratumoral hemorrhage or myxoid degenera-
tion despite therapeutic effects during the beginning of treat-
ment (25, 49-51). Because GIST, hypervascular neoplasm, ex-
hibits hypoattenuating findings resulting from reduced vascu-
larity, hyaline degeneration, and occasional cystic changes fol-
lowing imatinib treatment, the strict application of the response 
evaluation criteria in solid tumors (RECIST) or WHO criteria 
requires caution, and the development of new criteria is war-
ranted. Particularly for liver metastasis, when tumor response is 
determined solely based on the portal–venous phase CT, small 
and new lesions with hypodensity may be seen, which are most 
likely the resulting findings of clear margins secondary to ne-
crosis of preexisting tumors that were present before the treat-
ment with the same radiodensity as the hepatic parenchyma, 
and they require differential diagnosis (25, 51). Both tumor size 
and tumor density should be considered for the response eval-
uation. Improvement of patients’ symptoms or degree of a re-
duction in CT attenuation coefficient (Hounsefield Units, HU) 
or maximum standardized uptake value (SUVmax) on PET may 
be used to determine tumor response (25, 49-51). 
Recurrence and progression
Recurrence or progression includes appearance of a new lesion 
at the surgery site, development of a new metastasis, or an in-
crease in tumor size. In some cases, a new intratumoral nodule 
or an increased solid tissue in hypodense tumors previously re-
sponded is identified as recurrence or progression. The patterns 
of the progression cannot be determined based on the RECIST 
or WHO criteria, and thus inside and cell walls of each lesion 
should be examined very carefully (25, 52).
Treatment of disease progression during imatinib therapy
Resistance is classified into primary resistance and secondary 
resistance. Primary resistance is defined as progression within 
the first 6 months of imatinib therapy, and most of the cases 
progress multifocally (21). Secondary resistance is defined as 
progression after 6 months of the initiation of imatinib therapy, 
and generally two types of progression are seen (21, 25).
  Focal progression: It is called when one or a limited number 
of multiple lesions exhibits intratumoral nodules or lesions be-
come larger, which results in an increased FDG uptake on PET 
scan, and the remainder of the lesions are relatively well con-
trolled. Treatment for the focal progression requires multidisci-
plinary approaches. Local treatment such as resection of local-
ized metastasis to the liver or peritoneum, radiofrequency abla-
tion, as well as chemoembolization can be considered to con-
trol the focal progressing lesions. But, systemic treatment should 
be also continued to control hidden micrometastatic lesions. If 
local progressing lesion(s) was removed, standard dose of ima-
tinib can be continued. But, if those lesions were not removed, 
dose escalation of imatinib or switch to sunitinib should be con-
sidered. No prospective study on the efficacy of local treatment 
on focal progression has been conducted. Some studies suggest 
that a part of patients with focal progression may get benefit from 
local treatment on focal progression, but others eventually show 
general progression within short time after local treatment (33, 
34, 53). 
  General progression (multifocal resistance): It is called when 
the majority of multiple lesions simultaneously progress. The 
efficacy of local treatment on the multifocal resistance is ex-
tremely limited and mostly negative (33). Therefore, local treat-
ment for general progression is not recommended except for 
palliation of symptoms. Administration of imatinib at increased 
doses or second-line drug such as sunitinib should be consid-
ered.
  Increase of imatinib dose during disease progression: When 
disease progresses at the dose of 400 mg per day, an increase of 
imatinib to 800 mg per day has been known to show partial re-
sponses or control of tumors for a certain period in about 30-
40% of patients (43, 54). With the daily dose of 800 mg, adverse Kang Y-K, et al.  •  Diagnosis and Management of GIST in Korea
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events associated with imatinib are not increased except mal-
aise and anemia, but if an intolerable side effect occurs, it may 
be reduced to 600 mg per day (54). When severe adverse events 
are expected with direct dose escalation to 800 mg per day, ima-
tinib can be first escalated to 600 mg per day, and then sequen-
tially to 800 mg per day. The median progression-free survival is 
about 3 months and a 12-month progression-free survival rate 
is 18-30% with the dose escalation of imatinib (55).
  Use of sunitinib during disease progression: Sunitinib is a new 
tyrosine kinase inhibitor which can confer antitumor activity by 
both direct antitumor activity and antiangiogenic activity be-
cause it can inhibit VEGFR as well as kit or pdgfra (56). Suni-
tinib was approved for the treatment of patients with advanced 
GISTs after failure of the 1st line imatinib. A phase III pivotal 
study results showed that sunitinib at a dose of 50 mg daily with 
4 weeks on and 2 weeks off schedule was significantly superior 
in time to progression over placebo (median 27.3 weeks vs 6.4 
weeks, P<0.001) (56). Since progression during the rest period 
was occasionally observed, a continuous dosing schedule with 
a lower daily dose (37.5 mg per day) was also developed and 
proven to be effective and well tolerated, although no random-
ized trials have been performed to compare the intermittent 
and the continuous dosing schedule. So, the continuous dosing 
schedule with a lower daily dose can now be considered as an 
option on an individualized basis.
  Use of conventional cytotoxic chemotherapy during disease 
progression: No conventional cytotoxic chemotherapy has ever 
been reported to be effective in GISTs. Thus, we do not recom-
mend the use of such drugs except in clinical studies (21).
  Continuous use of imatinib or sunitinib after failure of both 
imatinib and sunitinib: There is no effective systemic treatment 
option after failure of both imatinib and sunitinib. And, general 
oncology principles indicate that the use of the same agent that 
already failed is not beneficial or recommended. However, in 
spite of resistance to these agents in a majority of tumor cells in 
this situation, at least a fraction of tumor cells may remain re-
sponsive to these agents. So, it is allowed and recommended in 
many countries to continue one of these agents to slow down 
the progression of the disease even after the tumor is determined 
resistant according to the RECIST criteria. For this indication, 
imatinib may be preferred to sunitinib and daily 400 mg ima-
tinib may be appropriate. However, this issue remains to be ad-
dressed in a well designed clinical trial.
CONCLUSION
Although several clinical practice guidelines for GIST based on 
clinical practice of each country have recently been published 
by the study group of each country (NCCN, ESMO, the Japan 
Society of Clinical Oncology, and in Australia), there was no stan-
dardized guideline for diagnosis or treatment of GISTs in Korea. 
To solve this problem, pathologists, surgeons, gastroenterolo-
gists, diagnostic radiologists, and medical oncologists organized 
a multidisciplinary study group called the Korean GIST Study 
Group (KGSG). We made the first guideline in 2007 for diagno-
sis and treatment of GISTs that is suitable for clinical practice in 
Korea. This study is the second version of the guideline for Ko-
rean GIST patients. Through series of workshops to review and 
discuss evolving new evidences, we have updated recent clini-
cal recommendations and reflected changes in diagnosis, sur-
gical and medical treatment for more optimal clinical practice 
for GIST in Korea. We hope the guideline can be of help in en-
hancing the quality of diagnosis by members of the Korean as-
sociate of physicians involving in GIST patients’ care and sub-
sequently in achieving optimal efficacy of treatment. 
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